<DOC>
	<DOCNO>NCT01990196</DOCNO>
	<brief_summary>Prostate cancer common cancer men second lead cause cancer death men . The purpose research study compare prostate cancer treat hormone therapy versus prostate cancer treat hormone therapy plus drug directly target cancer cell .</brief_summary>
	<brief_title>Neoadjuvant Phase 2 Study Comparing Effects AR Inhibition With/Without SRC MEK Inhibition Prostate Cancer</brief_title>
	<detailed_description>Most prostate cancer respond hormone therapy , also know chemical castration . Unfortunately , castration resistance may occur certain prostate cancer . Castration resistance hormone refractory prostate cancer mean cancer continue progress see progressively rise PSA and/or increase tumor mass bone scan , X-ray , CT scan MRI despite previous hormonal therapy . The researcher interested understanding mechanism castration resistance prostate cancer analyze prostate tissue radical prostatectomy ( prostate biopsy tissue ) radical prostatectomy ( whole prostate specimen ) . They look `` molecular signature '' prostate cancer cell hormone therapy identify key step cancer cell undergo become resistant hormone therapy . In addition , researcher use medication addition hormone therapy order block key biochemical step think mediate treatment resistance . This research provide crucial information development therapy improve clinical outcome patient advanced prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Inclusion Criteria ( patient must meet follow inclusion criterion participate study ) 1 . Willing able give inform consent . 2 . Adenocarcinoma prostate plan RP curative intent part standard care management plan . 3 . Patient candidate radical prostatectomy . 4 . Tumor accessible biopsy . 5 . Age ≥ 18 year . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 7 . Estimated life expectancy ≥ 6 month , 8 . Adequate organ function : normal renal , liver , hematologic , coagulation cardiac function : 1 . Absolute neutrophil count &gt; 1,500/µL , platelet count &gt; 100,000/µL , hemoglobin &gt; 5.6 mmol/L ( 9 g/dL ) Screening visit , 2 . Total bilirubin , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within normal range Screening visit , 3 . Creatinine &lt; 1.5 mg/dL Screening visit , 4 . INR &lt; 1.3 ( &lt; 3 warfarin anticoagulant ) Screening visit , 5 . Albumin &gt; 30 g/L ( 3.0 g/dL ) Screening visit , 6 . Left ventricular ejection fraction ( LVEF ) ≥ LLN ECHO MUGA , 9 . Patients clinically localize adenocarcinoma prostate schedule undergo radical prostatectomy ( RP ) curative intent follow clinicopathologic feature : ( 1 ) Gleason score sum ≥ 4+3 Gleason 5 , ( 2 ) PSA &gt; 20 , ( 3 ) clinical stage ≥ T3a ( stag MRI allow ) . 10 . Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel , 11 . Willing abstain procreative sex partake appropriate form contraception . For purpose study , condom use abstinence require . Exclusion Criteria ( candidate meet follow exclusion criterion exclude participation study ) 1 . Any prior treatment prostate cancer , 2 . Any nonadenocarcinoma histologic component , 3 . Any evidence lymphatic hematogenous metastasis , 4 . Clinically significant cardiovascular disease include : 1 . LVEF &lt; LLN 2 . History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month , 3 . Uncontrolled angina within 3 month , 4 . Congestive heart failure New York Heart Association ( NYHA ) class 3 4 , patient history congestive heart failure NYHA class 3 4 past , unless screen echocardiogram multigated acquisition scan perform within 3 month result leave ventricular ejection fraction ≥ 45 % , 5 . Any history congestive heart failure NYHA class patient assign Group 2 ( trametinib arm ) . 6 . History clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsades de pointes ) , 7 . Patients intracardiac defibrillator permanent pacemaker , 8 . Hypotension indicate systolic blood pressure &lt; 86 millimeter mercury ( mmHg ) Screening visit , 9 . Bradycardia indicate heart rate &lt; 50 beat per minute Screening ECG , 10 . Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHG and/or diastolic &gt; 90 mmHG control antihypertensive therapy , 11 . QTC ≥ 480 millisecond , 12 . Known cardiac metastasis . 5 . Presence comorbid disease medical condition would impair ability patient receive comply study protocol , 6 . History interstitial lung disease pneumonitis , 7 . History current evidence/risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) : History RVO CSR , predispose factor RVO CSR ( e.g . uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease hypertension , diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) . Visible retinal pathology assess ophthalmic exam consider risk factor RVO CSR : Evidence new optic disc cup Evidence new visual field defect Intraocular pressure &gt; 21 mm Hg 8 . Evidence coagulopathy , 9 . Patient receive therapeutic anticoagulation . 10 . Unwillingness engage adequate contraception , 11 . Allergy/sensitivity study drug ( degarelix , enzalutamide , trametinib , dasatinib ) , drug chemically relate study drug , excipients dimethylsulfoxide . 12 . Prior use degarelix , enzalutamide , trametinib , dasatinib context , 13 . Known suspected brain metastasis active leptomeningeal disease spinal cord compression . 14 . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV HCV infection permit ) . 15 . History seizure condition may predispose seizure ( e.g. , prior cortical stroke , significant brain trauma ) time past , 16 . History loss consciousness transient ischemic attack within past 12 month , 17 . Prior use androgen deprivation therapy radiation therapy , 18 . Gastrointestinal disorder affect absorption ( e.g. , gastrectomy , active peptic ulcer disease within last 3 month ) , 19 . Any major surgery , extensive radiotherapy , chemotherapy delay toxicity , biologic therapy , immunotherapy within 30 day enrollment and/or daily weekly chemotherapy without potential delayed toxicity within 14 day enrollment , 20 . Hospitalization within 30 day enrollment , 21 . History another malignancy within previous 5 year curatively treat nonmelanoma skin cancer , 22 . Use investigational agent within 4 week enrollment , 23 . Use herbal product may hormonal antiprostate cancer activity and/or know decrease PSA level ( e.g. , saw palmetto ) systemic corticosteroid great equivalent 10 mg prednisone per day within 4 week enrollment , 24 . Use medication know affect serum androgen level PSA , 25 . Any condition reason , opinion Investigator , interfere ability patient participate trial , place patient undue risk , complicate interpretation safety data .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>radical prostatectomy</keyword>
</DOC>